General Information
Version
8.2
Revision date
2023-08-27
Product name
Eurycomanone
CAS No.
84633-29-4
REACH No
A
Emergency telephone
+44 (0)870 8200418
Icons in SDS
Company Information
company name
Merck Life Science UK Limited
e-mail address of the competent person responsible for the Safety Data Sheet
TechnicalService@merckgroup.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H302
Hazard statements
Code
Statements
H302
Harmful if swallowed
Section 2
SECTION 2: Hazards identification
Labelling according Regulation (EC) No 1272/2008 as amended by GB-CLP Classification of the substance or mixture
Signal word
Warning Warning
Hazard statements
H302 Harmful if swallowed. Reduced Labeling (<= 125 ml) none
Precautionary statements
P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P301 + P312 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. P501 Dispose of contents/ container to an approved waste disposal plant. none
Supplemental label elements
none none
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
2.1 Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567 Acute toxicity, Oral (Category 4), H302 For the full text of the H-Statements mentioned in this Section, see Section 16.